Success Story: NIW Approved Despite RFE! Our Team Assisted a Chinese Process Chemist in Securing Success
Client’s Testimonial:
“The service from WeGreened is professional, and their response is usually quick. They are very experienced with the whole process of the GreenCard application. After the RFE notice was received in my case, the attorney provided the response strategy and instructions timely manner. Following the strategy, my case was finally approved after filing the documents. Their numerous successful historical cases provide them with the best strategy for the application. Thank you so much for your help!”
On November 26th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Process Chemist in the Field of Organic Chemistry (Approval Notice).
General Field: Organic Chemistry
Position at the Time of Case Filing: Process Chemist
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: November 26th, 2025
Processing Time: 12 months, 4 days
Case Summary:
This NIW approval highlights the achievements of a researcher with a Ph.D. in Chemistry whose work advances organic chemistry methods for drug development. When the client approached NAILG, the client was employed in a U.S. industry research role focused on process and synthetic chemistry, applying advanced expertise to improve how active pharmaceutical ingredients are produced at scale. NAILG recognized that the client’s proposed endeavor, developing practical and efficient routes to produce active pharmaceutical ingredients for drugs in clinical trials, directly supports the discovery of new treatments for diseases such as cancer and Alzheimer’s disease. The case received a Request for Evidence, and NAILG addressed it with strengthened documentation that reinforced both the national value of the endeavor and the client’s strong qualifications.
Substantial Merit and National Importance
The client’s proposed work targets a clear national and global challenge: accelerating the discovery and delivery of effective therapies for high-burden diseases. By improving synthetic routes and scalable production methods for active pharmaceutical ingredients, the client helps reduce costs, shorten development timelines, and increase reliability in pharmaceutical manufacturing. These advances support smoother clinical trial progress and broaden the pathway for new therapies for cancer, neurodegenerative disorders, and other serious conditions. NAILG emphasized that innovation at this level in organic synthesis carries substantial merit because it can translate into real improvements in public health and therapeutic access.
Research Influence and Scholarly Output
The client has authored 8 peer-reviewed journal articles reflecting sustained contributions to practical organic chemistry and pharmaceutical synthesis. The client’s published work has been cited 300+ times by independent researchers. This citation record demonstrates clear influence and shows that the client’s methods and findings are being used and built upon in ongoing drug development and synthetic chemistry research.
RFE Response and Case Strength
Although USCIS issued a Request for Evidence, NAILG responded with focused and persuasive materials clarifying the national importance of the client’s proposed work and strengthening the proof of the client’s ability to advance it. The approval after the RFE highlights both the depth of the client’s record and the effectiveness of NAILG’s strategy in presenting the case.
NIW Approval and Outlook
NAILG structured the NIW petition to show that the client’s endeavor has substantial merit and national importance, that the client is well-positioned through a proven publication and citation record, and that waiving the job-offer requirement benefits the United States. The final approval, even after an RFE, reflects USCIS recognition of the client’s influential role in advancing practical organic chemistry solutions for pharmaceutical innovation. NAILG is proud to support the client’s continued work toward stronger drug discovery and manufacturing pathways that can expand treatment options for serious diseases and reinforce U.S. leadership in biomedical and chemical research.